vTv医疗 VTVT 深 沪
等待开盘 11-05 09:30:00 美东时间
24.92
+1.520
+6.50%
华盛通- 最 高24.92
- 今 开23.01
- 成交量 5259股
- 最 低 23.01
- 昨 收 23.40
- 总市值 6522.06万
- 52周最高 26.99
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 13.15
- 委 比 -17.65%
- 总股本 261.72万
- 历史最高 560.00
- 量 比 0.73
- 振 幅 8.16%
- 历史最低 7.38
- 每 手 1
- 风险率 2.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
vTv Therapeutics has appointed four distinguished scientists to its Scientific Advisory Board to guide the clinical development of cadisegliatin, an oral adjunctive therapy for type 1 diabetes now in Phase 3 trials. The board includes leaders in diabetes research, clinical trial design, and regulatory science, aiming to provide strategic input on the advancement of cadisegliatin. The company is committed to advancing this innovative treatment, cu...
10-09 12:00
Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) rose sharply in pre-market ...
10-06 21:01
vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
vTv Therapeutics will present new preclinical data on TTP-RA, an oral RAGE antagonist, and cadisegliatin, a potential first-in-class oral glucokinase activator, at the INNODIA Symposium during the EASD Annual Meeting. TTP-RA showed potential to prevent type 1 diabetes (T1D) onset by restoring glucose homeostasis and modulating immune responses. Cadisegliatin is currently in a Phase 3 trial as a novel adjunctive therapy for T1D. vTv seeks partners...
09-15 12:00
vTv Therapeutics to Join Morgan Stanley Conference
The latest update is out from vTv Therapeutics ( ($VTVT) ). On September 10, 20...
09-11 01:29
vTv Therapeutics to Participate in Upcoming September Investor Conferences
vTv Therapeutics announced that its management will participate in two September investor conferences: the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, featuring 1x1 investor meetings, and the Morgan Stanley 23rd Annual Global Healthcare Conference on the same day, including a fireside chat from 2:35 PM to 3:10 PM EST and 1x1 investor meetings. The company, focused on developing cadisegliatin for type 1 diabetes,...
09-03 12:00
vTv Therapeutics announces $80M PIPE financing; shares up 14%
vTv Therapeutics (NASDAQ:VTVT) has entered into an $80M private placement in public equity financing. The financing includes participation from existing investors Samsara BioCapital and the T1D Fund, ...
09-02 20:59
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
vTv Therapeutics secures $80 million in private placement financing to support the ongoing Phase 3 CATT1 trial of cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes. The funding will help advance the development of cadisegliatin, which aims to reduce hypoglycemic events and improve glycemic control. The trial's topline data is expected in the second half of 2026. Key investors include Samsara BioCapital, T1D Fun...
09-02 12:00
vTv Therapeutics Q2 EPS $(0.92) Misses $(0.82) Estimate.
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.82) by 11.52 percent. This is a 13.58 percent decrease over losses of $(0.81) per share
08-13 04:17
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
vTv Therapeutics启动cadisegliatin的3期CATT1试验，预计2026年公布结果。其知识产权扩展，领导团队增强。第二季度现金储备降至2590万美元，净亏损600万美元。cadisegliatin作为潜在首创新药，用于治疗1型糖尿病。财务数据显示研发投入增加，净亏损扩大，反映了持续的研发投入。公司致力于缓解糖尿病患者低血糖风险，解决未满足的医疗需求。 ```html vTv Therapeutics启动了cadisegliatin的3期CATT1试验，预计2026年下半年公布结果。公司扩大了知识产权组合，并增强了领导团队。2025年第二季度现金储备为2590万美元，净亏损600万美元。cadisegliatin一种潜在首创新药，可作为胰岛素的辅助疗法用于治疗1型糖尿病。财务数据显示研发投入增加，净亏损扩大。公司致力于通过cadisegliatin缓解糖尿病患者的低血糖风险，解决未满足的医疗需求。 ```
08-12 20:15
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
vTv Therapeutics announced that the USPTO has granted a patent for crystalline forms of salts and co-crystals of cadisegliatin, strengthening its intellectual property protection. The patent, valid until 2041, supports the development of cadisegliatin as a potential first-in-class oral adjunctive therapy for type 1 diabetes. The company highlights its commitment to innovation and regulatory milestones.
08-11 12:00
